Depression
The Zombie Drugs- xylazine and medetomidine
Stealth additives to fentanyl is complicating opioid overdose and recovery.
Updated April 10, 2026 Reviewed by Hara Estroff Marano
Key points
- Adulterants medetomidine and xylazine increase opioid effects and is a newer polydrug of abuse.
- Users don’t know their fentanyl is laced with xylazine or medetomidine.
- Fentanyl plus xylazine—"tranq dope"—complicates emergency overdose treatment.
- Medetomidine syndrome begins with deep sedation from opioid and α2-agonist but switch to severe withdrawal
It’s not the zombie apocalypse—not even close—but most people who view users of the sedative xylazine, which is increasingly mixed with fentanyl in the illicit drug supply, say they resemble zombies, with unseeing staring eyes and a stiff, shuffling walk. Although xylazine is not approved for human use, recreational use of the agent, an alpha2 adrenergic agent dubbed “tranq,” has emerged. A more potent sedative—medetomidine—has begun to replace or augment xylazine in parts of the U.S. drug supply. Like xylazine, it is an α2-adrenergic agonist used in veterinary medicine, but it is both more potent and longer acting. Public health surveillance shows a rapid increase in its detection across multiple states, with nearly all samples also containing fentanyl. Unlike xylazine, however, medetomidine appears to produce a particularly severe withdrawal syndrome marked by hypertension, tachycardia, and autonomic instability—sometimes requiring ICU-level care.
More alarmingly, my colleagues in the addiction field are reporting significant increases in overdose deaths involving fentanyl/xylazine, prompting the Office of National Drug Control Policy to declare xylazine an emerging threat. According to a May 2024 public alert, alpha2 adrenergic agents like medetomidine have also entered the recreational opioid drug supply as fentanyl or heroin adulterants.
Most users don’t knowingly take xylazine or medetomidine. Instead, the drug is added to fentanyl by illegal drug manufacturers. University of Florida professor Bruce Goldberger told me, “To the best of my knowledge, users of fentanyl do not seek illicitly manufactured fentanyl with xylazine. Xylazine is ingested unknowingly.” He also notes, “Xylazine test strips are available to test powders for the presence of xylazine.”
However, some people do buy xylazine for abuse, especially in cities like Philadelphia. Pennsylvania (40.3%), New York (36.5%), and Ohio (34.6%) had the highest xylazine positivity rates over the year, and the top 20 states were all situated along or east of the Mississippi River in Fentanyl-Positive urine tests (Millennium Health July 16, 2024 Signals Alert). According to forensic expert John Thompson, M.D., chairman of psychiatry at Tulane, the combined drug is also found in New Orleans. “This xylazine adulteration trend must be publicized and limited before it becomes an even larger problem," he told me. "Imagine that in addition to the greater than 100,000 drug overdose deaths, we now add to that a generation of young people missing fingers, toes, and limbs.” He is referring to the extreme effects of xylazine on the skin.
Dr Thompson noted that xylazine is not a controlled substance under the Controlled Substances Act. However, xylazine causes profound sedation and hypotension and is associated with deep, unhealing wounds characterized by dark, dead tissue—independent of the injection site—putting users at high risk for amputations.
What Is Xylazine?
Xylazine, a depressant, was discovered as an antihypertensive agent in 1962 by Farbenfabriken Bayer in Germany. The drug was used to sedate animals in the late 1960s and is still used in horse and cattle surgeries.
Xylazine causes significant cardiovascular side effects, including bradycardia, hypotension, and respiratory depression. Medetomidine, a related drug, is generally more potent, with longer duration than xylazine.
Philadelphia: Zombie Central
The addition of xylazine gives the fentanyl legs. As fentanyl's effects normally begin to wear off and withdrawal would otherwise begin, xylazine instead is still active, causing sedation. This leads to prolonging the intoxicating effects of the fentanyl. The user may already be in withdrawal but is so sedated from the xylazine that they are not even aware of it. The epicenter of voluntary abuse of xylazine is Kensington Street in Philadelphia, where illegal drugs are openly used. This documentary video illustrates the problem.
Effects of Fentanyl/Xylazine
When individuals use drugs contaminated with xylazine, they seem heavily sedated or unconscious, with droopy eyelids and a vacant gaze. Their movements and speech are slow and uncoordinated, and the person appears in a trance. The drug's effects on the central nervous system may cause poor balance and coordination, making users stagger or stumble. Prolonged use of xylazine-contaminated drugs can result in severe non-healing skin ulcers and infections. Reduced blood flow and poor nutrition may cause skin to appear pale, gray, or discolored. The depressant effects may slow breathing, contributing to lethargy.
Overdose Deaths Involving Xylazine
From 2015 to 2020, deaths linked to xylazine increased nearly 20-fold. The monthly percentage of detected fentanyl-involved deaths with xylazine rose from 2.9% in January 2019 to 10.9% in June 2022, a 276% increase. Although Pennsylvania, and especially Philadelphia, is ground zero, dramatic increases in fentanyl/xylazine overdose are found throughout the U.S.
Harvard cardiologist Dan Blumenthal, M.D., told me, “Alpha-2 agonists like xylazine are peripheral vasodilators and lower blood pressure. Overdoses of these agents can result in dangerously low blood pressure and heart rate, both of which can compromise end-organ and peripheral perfusion, resulting in harm to the brain, heart, kidneys, and extremities.”
Xylazine or medetomidine overdose is not generally recognized.
Clinicians are now encountering a paradoxical syndrome: patients who are initially deeply sedated from combined opioid and α2-agonist exposure may later develop severe withdrawal characterized by agitation, hypertension, and autonomic instability. This pattern—particularly associated with medetomidine—can emerge within hours and peak over the next day, often requiring aggressive management beyond standard opioid withdrawal protocols.
Hypoxic Effects of Xylazine or Medetomidine
Xylazine or Medetomidine overdose is commonly encountered in combination with fentanyl, but it has also been detected in mixtures containing cocaine, heroin, and other drugs.
The most common side effects in humans include bradycardia, respiratory depression, hypotension, and changes in brain blood flow and oxygen.
While large decreases in brain oxygen levels could be tolerated if transient, harmful effects accelerate when hypoxia is prolonged; the hypoxic effects produced by fentanyl/xylazine are difficult to reverse and compromise long-term brain health.
Conclusion
Xylazine and medetomidine are growing threats nationwide, especially since most patients have no idea that fentanyl includes an alpha-2 veterinary medicine. Alongside sedatives, a new class of synthetic opioids—nitazenes—has quietly expanded in the illicit market. These compounds, many times more potent than morphine, have increased dramatically in forensic detections across the U.S. in recent years. Nearly all identified cases involve multiple substances, typically including fentanyl. This reinforces a key point: today’s overdose risk is not driven by a single drug, but by unpredictable combinations of highly potent agents.
We are entering a new phase of the overdose crisis defined by polysubstance exposure, where sedatives like xylazine and medetomidine combine with ultra-potent opioids like fentanyl and nitazenes—producing new clinical syndromes and new risks.
Addiction is a chronic, relapsing, long-term disease, often ending with premature death. Harm reduction is important but not a cure, as more than 20% of all opioid overdose decedents received some form of naloxone. Research, prevention, early identification, intervention, and treatment are all needed.
Fentanyl overdose itself causes respiratory depression, and overdose-related respiratory depression is a neurological emergency that may lead to brain hypoxia, brain cell loss, and, at worst, coma and death. Although all opioid overdoses can induce brain hypoxia, the danger is magnified with fentanyl/xylazine and related drugs. In addition, the hypoxic effects of heroin and fentanyl are significantly changed by recent consumption of alcohol, benzodiazepines, ketamine, medetomidine, or xylazine.
References
Kiyatkin EA and Choi S (2024) Brain oxygen responses induced by opioids: focus on heroin, fentanyl, and their adulterants. Front. Psychiatry 15:1354722. doi: 10.3389/fpsyt.2024.1354722
Smith MA, Biancorosso SL, Camp JD, Hailu SH, Johansen AN, Morris MH, Carlson HN. "Tranq-dope" overdose and mortality: lethality induced by fentanyl and xylazine. Front Pharmacol. 2023 Oct 26;14:1280289. doi: 10.3389/fphar.2023.1280289. PMID: 37954845; PMCID: PMC10637371.
Acosta-Mares P, Violante-Soria V, Browne T Jr, Cruz SL. Xylazine potentiates the lethal but not the rewarding effects of fentanyl in mice. Drug Alcohol Depend. 2023 Dec 1;253:110993. doi: 10.1016/j.drugalcdep.2023.110993. Epub 2023 Oct 20. PMID: 37883846.
Laffont CM, Purohit P, Delcamp N, Gonzalez-Garcia I and Skolnick P (2024) Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid
overdose on respiratory depression and cardiac arrest. Front. Psychiatry 15:1399803.
doi: 10.3389/fpsyt.2024.1399803


